UBA2

Summary

UBA2 (ubiquitin like modifier activating enzyme 2, HGNC:30661) is a protein-coding gene on chromosome 19q13.11, encoding SUMO-activating enzyme subunit 2 (Q9UBT2). The heterodimer acts as an E1 ligase for SUMO1, SUMO2, SUMO3, and probably SUMO4. It is a common-essential gene (DepMap: required in 99.1% of cancer cell lines).

Posttranslational modification of proteins by the addition of the small protein SUMO (see SUMO1; MIM 601912), or sumoylation, regulates protein structure and intracellular localization. SAE1 (MIM 613294) and UBA2 form a heterodimer that functions as a SUMO-activating enzyme for the sumoylation of proteins (Okuma et al., 1999 [PubMed 9920803]).

Source: NCBI Gene 10054 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ACCES syndrome (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 124 total — 12 pathogenic, 10 likely-pathogenic
• Phenotypes (HPO): 38
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.1% of screened cell lines (common-essential)
• MANE Select transcript: NM_005499

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30661
Approved symbol	UBA2
Name	ubiquitin like modifier activating enzyme 2
Location	19q13.11
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13058, HRIHFB2115
Ensembl gene	ENSG00000126261
Ensembl biotype	protein_coding
OMIM	613295
Entrez	10054

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000246548, ENST00000439527, ENST00000586313, ENST00000588585, ENST00000590048, ENST00000591016, ENST00000592672, ENST00000592791, ENST00000592841, ENST00000607361

RefSeq mRNA: 2 — MANE Select: NM_005499 NM_001411139, NM_005499

CCDS: CCDS12439, CCDS92583

Canonical transcript exons

ENST00000246548 — 17 exons

Exon	Start	End
ENSE00000862687	34428381	34428570
ENSE00000862690	34433348	34433412
ENSE00002813476	34469040	34471251
ENSE00003468579	34451981	34452147
ENSE00003496317	34458769	34458924
ENSE00003500032	34443844	34443911
ENSE00003504279	34434868	34434968
ENSE00003595902	34430576	34430659
ENSE00003601380	34454444	34454556
ENSE00003608749	34460470	34460566
ENSE00003660760	34438645	34438766
ENSE00003664506	34445000	34445121
ENSE00003669057	34431861	34431931
ENSE00003682170	34454260	34454353
ENSE00003695083	34464026	34464131
ENSE00003701944	34466878	34467014
ENSE00003791247	34450265	34450364

Expression profiles

Bgee: expression breadth ubiquitous, 204 present calls, max score 98.58.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 114.8419 / max 802.2854, expressed in 1827 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175144	114.8419	1827

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.58	gold quality
embryo	UBERON:0000922	98.46	gold quality
ganglionic eminence	UBERON:0004023	98.46	gold quality
calcaneal tendon	UBERON:0003701	98.43	gold quality
popliteal artery	UBERON:0002250	98.37	gold quality
tibial artery	UBERON:0007610	98.37	gold quality
cortical plate	UBERON:0005343	98.00	gold quality
right coronary artery	UBERON:0001625	97.82	gold quality
artery	UBERON:0001637	97.78	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	97.66	gold quality
aorta	UBERON:0000947	97.63	gold quality
left coronary artery	UBERON:0001626	97.34	gold quality
adrenal tissue	UBERON:0018303	97.10	gold quality
thoracic aorta	UBERON:0001515	97.08	gold quality
ascending aorta	UBERON:0001496	97.06	gold quality
islet of Langerhans	UBERON:0000006	97.02	gold quality
descending thoracic aorta	UBERON:0002345	96.95	gold quality
gastrocnemius	UBERON:0001388	96.89	gold quality
colonic epithelium	UBERON:0000397	96.74	gold quality
muscle of leg	UBERON:0001383	96.74	gold quality
right testis	UBERON:0004534	96.63	gold quality
stromal cell of endometrium	CL:0002255	96.56	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.54	gold quality
omental fat pad	UBERON:0010414	96.54	gold quality
peritoneum	UBERON:0002358	96.45	gold quality
left testis	UBERON:0004533	96.43	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	96.23	gold quality
cerebellar hemisphere	UBERON:0002245	96.19	gold quality
ectocervix	UBERON:0012249	96.10	gold quality
cerebellar cortex	UBERON:0002129	96.08	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	46.47
E-HCAD-10	yes	40.20
E-MTAB-8142	yes	36.85
E-GEOD-134144	yes	28.39
E-HCAD-11	yes	23.11
E-ANND-3	yes	11.25
E-CURD-112	no	2.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting UBA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-889-3P	99.40	69.76	2103
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-1911-3P	99.15	66.17	528

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.1% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 24)

• structures of heterodimeric Sae1/Sae2-Mg.ATP and Sae1/Sae2-SUMO-1-Mg.ATP complexes (PMID:15660128)
• UBA2 stabilizes APOBEC3G by preventing ubiquitin chain elongation and proteasome-mediated proteolysis. (PMID:18680593)
• The mammalian E1 subunits can be imported separately, identify nuclear localization signals (NLSs) in Aos1 and in Uba2, and demonstrate that their import is mediated by importin alpha/beta in vitro and in intact cells. (PMID:21209321)
• loss of SAE1/2 activity drives synthetic lethality with Myc; inactivation of SAE2 leads to mitotic catastrophe and cell death upon Myc hyperactivation; findings in Myc-high breast cancers suggest low tumor SAE1 and SAE2 correlates metastasis-free survival (PMID:22157079)
• Data show that the SAE2 subunit of the small ubiquitin-like modifier (SUMO) E1 is autoSUMOylated at residue Lys-236, and SUMOylation was catalyzed by Ubc9 at several additional Lys residues surrounding the catalytic Cys-173 of SAE2. (PMID:22403398)
• Data indicate the role of anti-SUMO activating enzyme SAE1 and SAE2 antibody as marker of dermatomyositis. (PMID:22884621)
• This study has identified the mechanism used to localize SAE to the nucleus. (PMID:23095757)
• Here, we show that hHR23A utilizes both the UBA2 and XPCB domains to form a stable complex with Vpr, linking Vpr directly to cellular DNA repair pathways and their probable exploitation by the virus. (PMID:24318982)
• We propose that disturbance of the SUMOylation pathway, mediated by pathogenic variants in UBA2, is a novel mechanism for aplasia cutis congenita and other phenotypic abnormalities. (PMID:28110515)
• Calcium/calpain-induced cleavage of the SAE2 leads to sumoylation inhibition reslting in bacillary dysentery. (PMID:29231810)
• the results suggest that Uba2 participates in the progression, invasion, and metastasis of colorectal cancer, and the possible mechanism is via regulating the Wnt signaling pathway and enhancing epithelial-mesenchymal transition behaviors of colorectal cancer cells. (PMID:29744931)
• The findings suggest that the UBA2-WTIP fusion is an oncogenic fusion gene, as well as a promising therapeutic target for the treatment of acute myeloid leukemia. (PMID:30179602)
• results from the present study indicated that UBA2 expression may enhance colorectal cancer cell proliferation and inhibit apoptosis. (PMID:30387828)
• Uba2 plays a vital role in gastric cancer cell migration and invasion, possibly by regulating the Wnt/beta-catenin signaling pathway and epithelial-mesenchymal transition. (PMID:30479464)
• Identifying UBA2 as a proliferation and cell cycle regulator in lung cancer A549 cells. (PMID:30848500)
• the results together with previous data such as the development of Split-hand/foot malformation (SHFM) in Lrp6 knockout mice, the presence of SHFM in two subjects with 19q13 deletions involving UBA2, and strong mouse Uba2 expression in the developing limb buds, imply that LRP6 and UBA2 represent plausible candidate genes for SHFM. (PMID:31332306)
• Increased SUMO-activating enzyme SAE1/UBA2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synoviocytes. (PMID:32938830)
• UBA2 activates Wnt/beta-catenin signaling pathway during protection of R28 retinal precursor cells from hypoxia by extracellular vesicles derived from placental mesenchymal stem cells. (PMID:33008487)
• Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics. (PMID:33979648)
• UBA2 variants underlie a recognizable syndrome with variable aplasia cutis congenita and ectrodactyly. (PMID:34040189)
• Genome sequencing in families with congenital limb malformations. (PMID:34159400)
• UBA2 promotes the progression of renal cell carcinoma by suppressing the p53 signaling. (PMID:34467471)
• UBA2 as a Prognostic Biomarker and Potential Therapeutic Target in Glioma. (PMID:38682183)
• UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway. (PMID:39013843)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	uba2	ENSDARG00000101332
mus_musculus	Uba2	ENSMUSG00000052997
rattus_norvegicus	Uba2	ENSRNOG00000021113
drosophila_melanogaster	Uba2	FBGN0029113
caenorhabditis_elegans	uba-2	WBGENE00006700

Paralogs (9): UBA6 (ENSG00000033178), UBA5 (ENSG00000081307), MOCS3 (ENSG00000124217), UBA1 (ENSG00000130985), SAE1 (ENSG00000142230), UBA3 (ENSG00000144744), NAE1 (ENSG00000159593), UBA7 (ENSG00000182179), ATG7 (ENSG00000197548)

Protein

Protein identifiers

SUMO-activating enzyme subunit 2 — Q9UBT2 (reviewed: Q9UBT2)

Alternative names: Anthracycline-associated resistance ARX, Ubiquitin-like 1-activating enzyme E1B, Ubiquitin-like modifier-activating enzyme 2

All UniProt accessions (6): Q9UBT2, K7EPL2, K7ES38, K7ESK7, U3KQ55, U3KQ93

UniProt curated annotations — full annotation on UniProt →

Function. The heterodimer acts as an E1 ligase for SUMO1, SUMO2, SUMO3, and probably SUMO4. It mediates ATP-dependent activation of SUMO proteins followed by formation of a thioester bond between a SUMO protein and a conserved active site cysteine residue on UBA2/SAE2.

Subunit / interactions. Heterodimer of SAE1 and UBA2/SAE2. The heterodimer corresponds to the two domains that are encoded on a single polypeptide chain in ubiquitin-activating enzyme E1. Interacts with UBE2I.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Sumoylated with SUMO1 and SUMO2/3 and by UBC9. Sumoylation at Lys-236 inhibits enzymatic activity. Sumoylation at the C-terminal lysine cluster plays an essential role in nuclear trafficking.

Disease relevance. ACCES syndrome (ACCES) [MIM:619959] An autosomal dominant syndrome characterized by a highly variable phenotypic spectrum. Clinical features include aplasia cutis congenita, thin scalp hair, dry skin, dental anomalies, ectrodactyly, and skeletal and neurodevelopmental abnormalities. Craniofacial, cardiac, renal and genital anomalies have also been reported. Affected individuals have early growth deficiencies that improve with age. The disease is caused by variants affecting the gene represented in this entry.

Pathway. Protein modification; protein sumoylation.

Similarity. Belongs to the ubiquitin-activating E1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UBT2-1	1	yes
Q9UBT2-2	2

RefSeq proteins (2): NP_001398068, NP_005490* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000594	ThiF_NAD_FAD-bd	Domain
IPR018074	UBQ-activ_enz_E1_CS	Conserved_site
IPR023318	Ub_act_enz_dom_a_sf	Homologous_superfamily
IPR028077	UAE_UbL_dom	Domain
IPR030661	Uba2	Family
IPR032426	UBA2_C	Domain
IPR033127	UBQ-activ_enz_E1_Cys_AS	Active_site
IPR035985	Ubiquitin-activating_enz	Homologous_superfamily
IPR042449	Ub-E1_IAD_1	Homologous_superfamily
IPR045886	ThiF/MoeB/HesA	Family

Pfam: PF00899, PF14732, PF16195

UniProt features (126 total): helix 28, strand 24, cross-link 16, mutagenesis site 12, binding site 10, turn 10, sequence variant 7, compositionally biased region 6, modified residue 5, sequence conflict 3, region of interest 2, chain 1, splice variant 1, active site 1

Structure

Experimental structures (PDB)

16 structures.

PDB	Method	Resolution (Å)
9QN5	X-RAY DIFFRACTION	1.97
6XOG	X-RAY DIFFRACTION	1.98
6XOI	X-RAY DIFFRACTION	2
5FQ2	X-RAY DIFFRACTION	2.2
6XOH	X-RAY DIFFRACTION	2.23
1Y8Q	X-RAY DIFFRACTION	2.25
3KYC	X-RAY DIFFRACTION	2.45
6CWY	X-RAY DIFFRACTION	2.46
4W5V	X-RAY DIFFRACTION	2.5
9IF6	X-RAY DIFFRACTION	2.51
3KYD	X-RAY DIFFRACTION	2.61
9DRJ	ELECTRON MICROSCOPY	2.7
1Y8R	X-RAY DIFFRACTION	2.75
6CWZ	X-RAY DIFFRACTION	3.1
9DQB	ELECTRON MICROSCOPY	3.6
2PX9	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBT2-F1	85.72	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 173 (glycyl thioester intermediate)

Ligand- & substrate-binding residues (10): 24–29; 48; 56–59; 72; 95–96; 117–122; 158; 161; 441; 444

Post-translational modifications (21): 207, 271, 507, 592, 613, 164, 190, 236, 236, 257, 257, 271, 275, 371, 420, 420, 540, 611, 613, 617 …

Mutagenesis-validated functional residues (12):

Position	Phenotype
56	abolishes atp-dependent activation of sumo proteins.
57	strongly reduces atp-dependent activation of sumo proteins.
59	strongly reduces atp-dependent activation of sumo proteins.
72	abolishes atp-dependent activation of sumo proteins.
117	abolishes atp-dependent activation of sumo proteins.
173	loss of enzyme activity.
174	slightly reduced enzyme activity.
184	no effect on enzyme activity.
235	strongly reduced interaction with ube2i; when associated with a-238.
238	strongly reduced interaction with ube2i; when associated with a-235.
484	strongly reduced interaction with ube2i.
485	strongly reduced interaction with ube2i.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-3065676	SUMO is conjugated to E1 (UBA2:SAE1)
R-HSA-3065678	SUMO is transferred from E1 to E2 (UBE2I, UBC9)
R-HSA-2990846	SUMOylation
R-HSA-3215018	Processing and activation of SUMO
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 307 (showing top): BORCZUK_MALIGNANT_MESOTHELIOMA_UP, MORF_SMC1L1, GOBP_REGULATION_OF_PROTEIN_SUMOYLATION, MORF_UBE2I, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_HDAC1, MORF_UBE2N, MORF_RAD21, MORF_HDAC2, CTATGCA_MIR153, ATGTTAA_MIR302C, PATIL_LIVER_CANCER, PUJANA_CHEK2_PCC_NETWORK, GOBP_PEPTIDYL_LYSINE_MODIFICATION, MORF_SKP1A

GO Biological Process (2): protein sumoylation (GO:0016925), positive regulation of protein sumoylation (GO:0033235)

GO Molecular Function (12): magnesium ion binding (GO:0000287), ATP binding (GO:0005524), transferase activity (GO:0016740), SUMO activating enzyme activity (GO:0019948), SUMO binding (GO:0032183), small protein activating enzyme binding (GO:0044388), ubiquitin-like protein conjugating enzyme binding (GO:0044390), protein heterodimerization activity (GO:0046982), nucleotide binding (GO:0000166), protein binding (GO:0005515), ubiquitin-like modifier activating enzyme activity (GO:0008641), metal ion binding (GO:0046872)

GO Cellular Component (5): nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), SUMO activating enzyme complex (GO:0031510), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Processing and activation of SUMO	2
Post-translational protein modification	1
SUMOylation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
enzyme binding	2
nuclear lumen	2
cellular anatomical structure	2
peptidyl-lysine modification	1
protein modification by small protein conjugation	1
protein sumoylation	1
regulation of protein sumoylation	1
positive regulation of protein modification by small protein conjugation or removal	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
catalytic activity	1
ubiquitin-like modifier activating enzyme activity	1
ubiquitin-like protein binding	1
protein dimerization activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
ligase activity, forming carbon-sulfur bonds	1
catalytic activity, acting on a protein	1
ATP-dependent activity	1
cation binding	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
nuclear protein-containing complex	1
catalytic complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

3476 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBA2	UBE2I	P50550	993
UBA2	SAE1	Q9UBE0	993
UBA2	SUMO1	P55856	971
UBA2	SUMO2	P55855	945
UBA2	RANGAP1	P46060	908
UBA2	RAD23A	P54725	855
UBA2	SENP1	Q9P0U3	851
UBA2	NEDD8	Q15843	810
UBA2	PIAS3	Q9Y6X2	776
UBA2	PIAS2	O75928	772
UBA2	LSM14A	Q8ND56	771
UBA2	SENP3	Q9H4L4	744
UBA2	NSMCE2	Q96MF7	737
UBA2	RANBP2	P49792	720
UBA2	USP5	P45974	718

IntAct

83 interactions, top by confidence:

A	B	Type	Score
UBA2	SAE1	psi-mi:“MI:0407”(direct interaction)	0.950
SAE1	UBA2	psi-mi:“MI:0407”(direct interaction)	0.950
UBA2	SAE1	psi-mi:“MI:0915”(physical association)	0.950
SAE1	UBA2	psi-mi:“MI:0915”(physical association)	0.950
SUMO1	UBA2	psi-mi:“MI:0915”(physical association)	0.850
UBA2	SUMO1	psi-mi:“MI:0915”(physical association)	0.850
UBA2	SUMO1	psi-mi:“MI:0407”(direct interaction)	0.850
UBE2I	UBA2	psi-mi:“MI:0407”(direct interaction)	0.850
UBA2	UBE2I	psi-mi:“MI:0566”(sumoylation reaction)	0.850
UBE2I	UBA2	psi-mi:“MI:0566”(sumoylation reaction)	0.850
SAE1	SUMO1	psi-mi:“MI:0915”(physical association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SUMO1P1	UBA2	psi-mi:“MI:0915”(physical association)	0.560
UBA2	SUMO1P1	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	UBA2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (327): UBA2 (Two-hybrid), SUMO1P1 (Two-hybrid), UBE2I (Biochemical Activity), SUMO1 (Reconstituted Complex), UBE2I (Biochemical Activity), SAE1 (Two-hybrid), FOXK1 (Co-fractionation), PSMA3 (Co-fractionation), PSMA4 (Co-fractionation), PSMB3 (Co-fractionation), SAE1 (Co-fractionation), UBA2 (Co-fractionation), UBA2 (Co-fractionation), UBA2 (Co-fractionation), UBA2 (Co-fractionation)

ESM2 similar proteins: A0A0G2KTI4, A0A7U2QYM2, O00763, O55236, O60942, P10687, P10894, P29074, P48722, P55014, P55015, P91926, P97789, Q03330, Q07722, Q13621, Q15147, Q28BT8, Q28EX9, Q28GH3, Q29N38, Q338B9, Q4V7N2, Q59WH0, Q641F1, Q642Q1, Q66HV4, Q6DI37, Q6H8D6, Q6NY98, Q6YXZ7, Q756G9, Q7QG73, Q7SXG4, Q7ZVX6, Q7ZY60, Q8BPM2, Q8C878, Q8WZM0, Q924I2

Diamond homologs: A1A4L8, A1CAZ7, A1DED8, A2BDX3, A2R3H4, A3ACF3, A3LQF9, A4RPM5, A5DMB6, A5DSR2, A5GFZ6, A6ZT19, A7F582, A7THV5, A8WRE3, B0W377, B0WQV1, B0Y0P7, B3LSM6, B3MLX7, B3NUC9, B4FAT0, B4GKQ3, B4HYP0, B4IK21, B4JBC4, B4JIY0, B4KI53, B4L1K2, B4LRB9, B4M357, B4N7R4, B4NXF7, B4PYA4, B4R345, B5DS72, B5VK45, B6TNK6, D1GY43, D4GSF3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
UBA2	“form complex”	“SAE1/SAE2 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 64 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of SUMOylation proteins	5	37.1×	2e-05
SUMOylation of RNA binding proteins	6	32.4×	3e-06
SUMOylation of DNA replication proteins	5	28.2×	4e-05
SUMOylation of transcription cofactors	5	27.6×	4e-05
SUMOylation of DNA damage response and repair proteins	7	23.3×	3e-06
SUMOylation of chromatin organization proteins	6	21.6×	2e-05
SARS-CoV-2 activates/modulates innate and adaptive immune responses	6	12.2×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	12
Likely pathogenic	10
Uncertain significance	68
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (22)

Variant ID	HGVS	Classification
1696427	NM_005499.3(UBA2):c.1324dup (p.Tyr442fs)	Pathogenic
1696428	NM_005499.3(UBA2):c.327del (p.Phe109fs)	Pathogenic
1696429	NM_005499.3(UBA2):c.612del (p.Glu205fs)	Pathogenic
1801368	NM_005499.3(UBA2):c.1118del (p.Arg373fs)	Pathogenic
3024531	NM_005499.3(UBA2):c.649+1G>A	Pathogenic
3064270	NM_005499.3(UBA2):c.460-2A>G	Pathogenic
3375345	NM_005499.3(UBA2):c.336dup (p.Met113fs)	Pathogenic
3767658	NM_005499.3(UBA2):c.650-1G>C	Pathogenic
521193	NM_005499.3(UBA2):c.816_817del (p.Trp273fs)	Pathogenic
523936	NM_005499.3(UBA2):c.1376dup (p.Thr460fs)	Pathogenic
654989	NM_005499.3(UBA2):c.364C>T (p.Arg122Ter)	Pathogenic
977797	NM_005499.3(UBA2):c.800T>A (p.Leu267Ter)	Pathogenic
2584538	NM_005499.3(UBA2):c.1173_1174dup (p.Ala392fs)	Likely pathogenic
3349701	NM_005499.3(UBA2):c.806del (p.Met269fs)	Likely pathogenic
3370512	NM_005499.3(UBA2):c.319C>T (p.Arg107Ter)	Likely pathogenic
4086135	NM_005499.3(UBA2):c.582-1G>C	Likely pathogenic
4280641	NM_005499.3(UBA2):c.1038+1G>A	Likely pathogenic
4527602	NM_005499.3(UBA2):c.357_358del (p.Arg119fs)	Likely pathogenic
4796799	NM_005499.3(UBA2):c.439C>T (p.Gln147Ter)	Likely pathogenic
4819087	NM_005499.3(UBA2):c.149A>G (p.Asp50Gly)	Likely pathogenic
979177	NM_005499.3(UBA2):c.167A>C (p.Asn56Thr)	Likely pathogenic
979178	NM_005499.3(UBA2):c.1447G>A (p.Glu483Lys)	Likely pathogenic

SpliceAI

2531 predictions. Top by Δscore:

Variant	Effect	Δscore
19:34428568:CTGGT:C	donor_loss	1.0000
19:34428571:GTGA:G	donor_loss	1.0000
19:34428572:T:G	donor_loss	1.0000
19:34431929:G:GT	donor_gain	1.0000
19:34431929:GAA:G	donor_gain	1.0000
19:34431932:G:GG	donor_gain	1.0000
19:34431942:G:GG	donor_gain	1.0000
19:34433346:A:AG	acceptor_gain	1.0000
19:34433347:G:GG	acceptor_gain	1.0000
19:34433347:GCCCT:G	acceptor_gain	1.0000
19:34434860:A:AG	acceptor_gain	1.0000
19:34434863:TCCA:T	acceptor_loss	1.0000
19:34434866:A:AG	acceptor_gain	1.0000
19:34434866:AGCT:A	acceptor_gain	1.0000
19:34434867:G:GT	acceptor_gain	1.0000
19:34434867:GC:G	acceptor_gain	1.0000
19:34434867:GCT:G	acceptor_gain	1.0000
19:34434867:GCTG:G	acceptor_gain	1.0000
19:34434867:GCTGC:G	acceptor_gain	1.0000
19:34434955:C:G	donor_gain	1.0000
19:34434966:AAGGT:A	donor_loss	1.0000
19:34434967:AGGTA:A	donor_loss	1.0000
19:34434968:GGTAA:G	donor_loss	1.0000
19:34434969:G:GA	donor_loss	1.0000
19:34434969:G:GG	donor_gain	1.0000
19:34434970:T:A	donor_loss	1.0000
19:34438767:G:GG	donor_gain	1.0000
19:34443843:GCCA:G	acceptor_gain	1.0000
19:34443907:TGCCT:T	donor_gain	1.0000
19:34443908:GCCT:G	donor_gain	1.0000

AlphaMissense

4243 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:34428502:G:A	G24R	1.000
19:34428502:G:C	G24R	1.000
19:34428502:G:T	G24W	1.000
19:34430585:G:C	D50H	1.000
19:34430586:A:C	D50A	1.000
19:34430586:A:T	D50V	1.000
19:34430587:T:A	D50E	1.000
19:34430587:T:G	D50E	1.000
19:34430591:A:T	I52F	1.000
19:34430592:T:A	I52N	1.000
19:34430600:A:C	S55R	1.000
19:34430602:C:A	S55R	1.000
19:34430602:C:G	S55R	1.000
19:34430603:A:G	N56D	1.000
19:34430605:C:A	N56K	1.000
19:34430605:C:G	N56K	1.000
19:34430607:T:A	L57H	1.000
19:34430607:T:C	L57P	1.000
19:34430611:C:A	N58K	1.000
19:34430611:C:G	N58K	1.000
19:34430612:A:G	R59G	1.000
19:34430613:G:C	R59T	1.000
19:34430613:G:T	R59I	1.000
19:34430614:A:C	R59S	1.000
19:34430614:A:T	R59S	1.000
19:34430617:G:C	Q60H	1.000
19:34430617:G:T	Q60H	1.000
19:34430618:T:C	F61L	1.000
19:34430619:T:C	F61S	1.000
19:34430620:T:A	F61L	1.000

dbSNP variants (sampled 300 via entrez): RS1000087071 (19:34467663 C>G), RS1000090604 (19:34463058 C>G,T), RS1000094275 (19:34428683 G>T), RS1000145096 (19:34456344 C>T), RS1000164033 (19:34444732 A>G), RS1000234210 (19:34440140 A>C,G), RS1000341773 (19:34468511 T>C,G), RS1000352764 (19:34439488 C>G), RS1000433483 (19:34428665 C>T), RS1000487870 (19:34427478 T>C), RS1000531677 (19:34457794 G>T), RS1000579087 (19:34449380 C>T), RS1000585031 (19:34451715 T>A), RS1000702554 (19:34464884 T>C,G), RS1000818715 (19:34458700 A>G)

Disease associations

OMIM: gene MIM:613295 | disease phenotypes: MIM:619959, MIM:613026, MIM:183600

GenCC curated gene-disease

Disease	Classification	Inheritance
ACCES syndrome	Definitive	Autosomal dominant
multiple congenital anomalies/dysmorphic syndrome	Strong	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
ACCES syndrome	Definitive	AD

Mondo (4): ACCES syndrome (MONDO:0859262), chromosome 19q13.11 deletion syndrome, distal (MONDO:0700107), split hand-foot malformation (MONDO:0016576), multiple congenital anomalies/dysmorphic syndrome (MONDO:0019042)

Orphanet (1): Isolated split hand-split foot malformation (Orphanet:2440)

HPO phenotypes

38 total (30 of 38 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000085	Horseshoe kidney
HP:0000278	Retrognathia
HP:0000348	High forehead
HP:0000369	Low-set ears
HP:0000411	Protruding ear
HP:0000486	Strabismus
HP:0000729	Autistic behavior
HP:0000750	Delayed speech and language development
HP:0001057	Aplasia cutis congenita
HP:0001263	Global developmental delay
HP:0001270	Motor delay
HP:0001362	Calvarial skull defect
HP:0001385	Hip dysplasia
HP:0001508	Failure to thrive
HP:0001770	Toe syndactyly
HP:0001839	Split foot
HP:0002205	Recurrent respiratory infections
HP:0002209	Sparse scalp hair
HP:0002558	Supernumerary nipple
HP:0002575	Tracheoesophageal fistula
HP:0002827	Hip dislocation
HP:0003010	Prolonged bleeding time
HP:0003577	Congenital onset
HP:0004209	Clinodactyly of the 5th finger
HP:0004348	Abnormality of bone mineral density
HP:0004471	Aplasia cutis congenita over the scalp vertex
HP:0006101	Finger syndactyly
HP:0007383	Congenital localized absence of skin
HP:0007385	Aplasia cutis congenita of scalp

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST009391_387	Metabolite levels	5.000000e-06
GCST009391_543	Metabolite levels	3.000000e-06
GCST009391_885	Metabolite levels	7.000000e-06
GCST009391_958	Metabolite levels	3.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0010437	triacylglycerol 58:10 measurement
EFO:0010439	triacylglycerol 58:12 measurement
EFO:0010444	triacylglycerol 60:12 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL1615389 (SINGLE PROTEIN), CHEMBL2095174 (PROTEIN COMPLEX), CHEMBL3137290 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 41,249 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1231160	PEVONEDISTAT	3	1,480
CHEMBL33864	LIPOIC ACID, ALPHA	3	19,339
CHEMBL269277	BETULINIC ACID	1	20,430

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

36 measured of 134 human assays (135 total across all organisms); most potent 36 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
MLS000079917	EC50	0.0133 nM
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-phenylpyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-[(1R,2R,3S,4R)-2,3-dihydroxy-4-{[2-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-[(1R,2R,3S,4R)-4-{[2-(2,4-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrazolo[1,5-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(quinolin-3-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-Dihydroxy-4-((2-(3-phenoxyphenyl)pyrazolo[1,5-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(2-(trifluoromethyl)pyridin-4-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-Dihydroxy-4-((2-(5-(trifluoromethyl)thiophen-2-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(6-(trifluoromethyl)pyridin-2-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(2-phenoxyphenyl)pyrazolo[1,5-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(3-benzylpenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)-2,3-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(3-benzoylphenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-[(1R,2R,3S,4R)-2,3-dihydroxy-4-{[2-(1H-indol-5-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(2-(trifluoromethylthio)phenyl)pyrazolo[1,5-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(4-(trifluoromethylthio)phenyl)pyrazolo[1,5-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(6-chlorobenzo[b]thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(5-ethylbenzo[b]thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(s.e.)-((1R,2R,3S,4R)-4-(2-(2,4-dichloronaphthalen-1-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	55 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-{(1R,2R,3S,4R)-2,3-dihydroxy-4-[(5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-{(1R,2R,3S,4R)-4-[(5-chloro-2-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2,3-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(2-(4-bromophenyl)-5-chloropyrazolo[1,5-a]pyrimidin-7-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-{[5-chloro-2-(1-naphthyl)pyrazolo[1,5-a]pyrimidin-7-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-((1R,2R,3S,4R)-4-(5-chloro-2-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-[(1R,2R,3S,4R)-4-{[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]-pyrimidin-7-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(rac)-{(1R,2R,3S,4R)-2,3-dihydroxy-4-[(6-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(s.e.)-{(1R,2R,3S,4R)-4-[(3,6-dichloro-2-{3-	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
(s.e.)-{(1R,2R,3S,4R)-4-[(6-chloro-2-{3-[(trifluoromethyl)sulfanyl]phenyl}pyrazolo[1,	IC50	550 nM	US-9796725: Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
1-benzyl-N-butyl-2-[(2-chlorobenzoyl)amino]pyrrolo[3,2-b]quinoxaline-3-carboxamide	IC50	1100 nM	US-9045483: Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines
MLS000588669	IC50	1610 nM
N-(1-butyl-3-cyano-6,7-dimethylpyrrolo[3,2-b]quinoxalin-2-yl)-4-chlorobenzamide	IC50	4500 nM	US-9045483: Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines
N-(1-butyl-3-cyanopyrrolo[3,2-b]quinoxalin-2-yl)furan-2-carboxamide	IC50	5700 nM	US-9045483: Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines
MLS000068755	IC50	6150 nM
MLS000054842	IC50	23500 nM
3-(benzenesulfonyl)-1-butylpyrrolo[3,2-b]quinoxalin-2-amine	IC50	64000 nM	US-9045483: Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines
N-[3-(benzenesulfonyl)-1-butylpyrrolo[3,2-b]quinoxalin-2-yl]benzamide	IC50	98000 nM	US-9045483: Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines

ChEMBL bioactivities

490 potent at pChembl≥5 of 853 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	IC50	0.1	nM	CHEMBL4878832
10.00	IC50	0.1	nM	CHEMBL4858933
9.70	IC50	0.2	nM	CHEMBL4860263
9.70	IC50	0.2	nM	CHEMBL4854038
9.70	IC50	0.2	nM	CHEMBL4864361
9.70	IC50	0.2	nM	CHEMBL4850183
9.70	IC50	0.2	nM	CHEMBL4873487
9.52	IC50	0.3	nM	CHEMBL4848442
9.52	IC50	0.3	nM	CHEMBL4852516
9.52	IC50	0.3	nM	CHEMBL4860917
9.52	IC50	0.3	nM	CHEMBL4848140
9.40	IC50	0.4	nM	CHEMBL4870385
9.40	IC50	0.4	nM	CHEMBL4877684
9.40	IC50	0.4	nM	CHEMBL4856793
9.40	IC50	0.4	nM	CHEMBL4848114
9.40	IC50	0.4	nM	CHEMBL4873956
9.30	IC50	0.5	nM	CHEMBL4861509
9.22	IC50	0.6	nM	CHEMBL4847817
9.15	IC50	0.7	nM	CHEMBL4864280
9.15	IC50	0.7	nM	CHEMBL4874906
9.15	IC50	0.7	nM	CHEMBL4862248
9.10	IC50	0.8	nM	CHEMBL4856040
9.00	IC50	1	nM	CHEMBL4878088
9.00	IC50	1	nM	CHEMBL4870143
9.00	IC50	1	nM	CHEMBL4853360
9.00	IC50	1	nM	CHEMBL4860263
9.00	IC50	1	nM	CHEMBL4849766
9.00	IC50	1	nM	CHEMBL4862901
9.00	IC50	1	nM	CHEMBL4865157
8.96	IC50	1.1	nM	CHEMBL4865787
8.96	IC50	1.1	nM	CHEMBL4861240
8.96	IC50	1.1	nM	CHEMBL4862322
8.92	IC50	1.2	nM	CHEMBL4860960
8.89	IC50	1.3	nM	CHEMBL4855964
8.82	IC50	1.5	nM	CHEMBL4862248
8.80	IC50	1.6	nM	CHEMBL4851718
8.77	IC50	1.7	nM	CHEMBL4866755
8.77	IC50	1.7	nM	CHEMBL4860740
8.77	IC50	1.7	nM	CHEMBL4862587
8.70	IC50	2	nM	CHEMBL4865086
8.70	IC50	2	nM	CHEMBL4852740
8.70	IC50	2	nM	CHEMBL4866614
8.68	IC50	2.1	nM	CHEMBL4869144
8.64	IC50	2.3	nM	CHEMBL4860471
8.60	IC50	2.5	nM	CHEMBL4861656
8.54	IC50	2.9	nM	CHEMBL4859486
8.52	IC50	3	nM	CHEMBL4867650
8.52	IC50	3	nM	CHEMBL4856793
8.49	IC50	3.2	nM	CHEMBL4866833
8.44	IC50	3.6	nM	CHEMBL4872222

PubChem BioAssay actives

182 with measured affinity, of 258 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(1R,2R,3S,4R)-4-[[5-[4-[1-(6-bromo-2-pyridinyl)-1-hydroxyethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2,3-dihydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0001	uM
[(1R,2S,4R)-4-[[5-[4-(2-chloro-6,8-dihydro-5H-pyrano[3,4-b]pyridin-8-yl)-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0001	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-[(6-chloro-2-pyridinyl)-hydroxymethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0002	uM
[(1R,2S,4R)-4-[[5-[4-[1-(3-chlorophenyl)-1-hydroxyethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0002	uM
[(1R,2S,4R)-4-[[5-[4-[(3-chlorophenyl)-hydroxymethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0002	uM
[(1R,2S,4R)-4-[[5-[4-[amino-(3-chlorophenyl)methyl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0002	uM
[(1R,2S,4R)-4-[[5-[4-(6,8-dihydro-5H-pyrano[3,4-b]pyridin-8-yl)-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0002	uM
[(1R,2S,4R)-4-[[5-[4-(3,4-dihydro-1H-isochromen-1-yl)-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0003	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-[(3-chlorophenyl)-hydroxymethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0003	uM
[(1R,2S,4R)-4-[[5-[4-[(3-chlorophenyl)-hydroxymethyl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0003	uM
[(1R,2S,4R)-4-[[5-[4-[1-amino-1-(3-chlorophenyl)ethyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0003	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-(7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0004	uM
[(1R,2S,4R)-4-[[5-[4-(7-chloro-3,4-dihydro-1H-isochromen-1-yl)-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0004	uM
[(1R,2S,4R)-4-[[5-[4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0004	uM
[(1R,2S,4R)-4-[[5-[4-[amino-(3-chlorophenyl)methyl]-5-chlorothiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0004	uM
[(1R,2S,4R)-4-[[5-[1-[(3-bromophenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0004	uM
[(1R,2S,4R)-4-[[5-[4-(7-chloro-3,4-dihydro-1H-isochromen-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0005	uM
[(1R,2S,4R)-4-[[5-[1-[(3-bromophenyl)methyl]pyrrole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0006	uM
[(1R,2S,4R)-4-[[5-[1-[(6-bromo-2-pyridinyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0007	uM
[(1R,2S,4R)-4-[[5-[1-[(3-chlorophenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0007	uM
[(1R,2S,4R)-4-[[5-[4-[amino-(3-chlorophenyl)methyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0007	uM
[(1R,2S,4R)-4-[[5-[4-(7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0008	uM
[(1R,2R,3S,4R)-4-[[5-(1-benzylpyrazole-3-carbonyl)pyrimidin-4-yl]amino]-2,3-dihydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-(7-chloro-3,4-dihydro-1H-isochromen-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-4-[[5-[4-[(3-chlorophenyl)methyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-2-hydroxy-4-[[5-[4-(1,2,3,4-tetrahydroisoquinolin-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]cyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-4-[[5-[1-[(6-chloro-2-pyridinyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0010	uM
[(1R,2S,4R)-4-[[5-[1-[(5-chlorofuran-2-yl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0011	uM
[(1R,2S,4R)-2-hydroxy-4-[[5-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]cyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0011	uM
[(1R,2S,4R)-4-[[5-[1-[(3-ethynylphenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0011	uM
[(1R,2S,4R)-4-[[5-[4-[(3-chlorophenyl)methyl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0012	uM
[(1R,2S,4R)-4-[[5-[4-[(3-bromophenyl)methyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0013	uM
[(1R,2S,4R)-4-[[5-[4-(6-chloro-2,3-dihydro-1H-isoindol-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0016	uM
[(1R,2S,4R)-4-[[5-(1-benzylpyrrole-3-carbonyl)pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0017	uM
[(1R,2S,4R)-2-hydroxy-4-[[5-[1-[(3-methylphenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]cyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0017	uM
[(1R,2S,4R)-4-[[5-[4-(5-chloro-3,4-dihydro-1H-isochromen-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0017	uM
[(1R,2S,4R)-4-[[5-[1-[(5-chlorothiophen-2-yl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0020	uM
[(1R,2S,4R)-4-[[5-(1-benzylpyrazole-3-carbonyl)pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0020	uM
[(1R,2S,4R)-4-[[5-[5-[(3-bromophenyl)methyl]furan-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0020	uM
[(1R,2S,4R)-2-hydroxy-4-[[5-[1-[[3-(trifluoromethoxy)phenyl]methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]cyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0021	uM
[(1R,2R,3R,4R)-4-[[5-(1-benzylpyrazole-3-carbonyl)pyrimidin-4-yl]amino]-3-fluoro-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0023	uM
[(1R,2S,4R)-4-[[5-[4-(7-chloro-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0025	uM
[(1R,2S,4R)-4-[[5-[1-[(3-fluorophenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0029	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-(6-chloro-1,3-dihydro-2-benzofuran-1-yl)thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0030	uM
[(1R,2S,4R)-4-[[5-[1-[(2-chlorophenyl)methyl]pyrazole-3-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0032	uM
[(1R,2S,4R)-4-[[5-[5-chloro-4-[(3-chlorophenyl)methyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0036	uM
[(1R,2S,4R)-4-[[5-[4-[(3-chlorophenyl)-(methylamino)methyl]thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0037	uM
[(1R,2R,3S,4R)-4-[[5-(1-benzylpyrazole-3-carbonyl)pyrimidin-4-yl]amino]-3-fluoro-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0038	uM
[(1R,2R,4R)-4-[[5-(1-benzylpyrazole-3-carbonyl)pyrimidin-4-yl]amino]-3,3-difluoro-2-hydroxycyclopentyl]methyl sulfamate	1775495: Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km concentration by HTRF assay	ic50	0.0039	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
Benzo(a)pyrene	increases expression, affects methylation	2
aristolochic acid I	decreases expression, increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
1,6-hexamethylene diisocyanate	affects expression	1
trimellitic anhydride	affects expression	1
ammonium hexachloroplatinate	affects expression	1
aflatoxin B2	decreases methylation	1
1-UFT protocol	decreases response to substance	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Aspirin	increases expression	1
Benztropine	affects cotreatment, decreases expression	1
Clozapine	affects cotreatment, increases expression	1
Cuprizone	affects cotreatment, decreases expression, increases expression	1
Dietary Carbohydrates	decreases expression	1
Gold	decreases expression	1
Ivermectin	decreases expression	1
Nicotine	increases expression, increases sumoylation	1
Ozone	affects expression, increases abundance	1
Rotenone	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

32 unique, capped per target: 30 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652744	Binding	Binding affinity to human UBA2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem
CHEMBL1614105	Functional	PUBCHEM_BIOASSAY: AlphaScreen confirmatory assay for validation of inhibitors of SUMOylation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2006, AID2011, AID2069, AID2614, AID2658]	PubChem BioAssay data set

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.